Anticancer agent-based marine natural products and related compounds
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anticancer agent-based marine natural products and related compounds
Authors
Keywords
-
Journal
JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
Volume 17, Issue 2, Pages 199-216
Publisher
Informa UK Limited
Online
2015-01-04
DOI
10.1080/10286020.2014.996140
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors
- (2014) Marta Martínez-Díez et al. BIOCHEMICAL PHARMACOLOGY
- A Novel Immunomodulatory Hemocyanin from the Limpet Fissurella latimarginata Promotes Potent Anti-Tumor Activity in Melanoma
- (2014) Sergio Arancibia et al. PLoS One
- Plitidepsin: an orphan drug
- (2013) Alina Danu et al. Expert Opinion on Orphan Drugs
- Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab
- (2012) Nora M. Barboza et al. CANCER BIOLOGY & THERAPY
- Lessons from the Past and Charting the Future of Marine Natural Products Drug Discovery and Chemical Biology
- (2012) William H. Gerwick et al. CHEMISTRY & BIOLOGY
- Eribulin Mesylate (E7389): Review of Efficacy and Tolerability in Breast, Pancreatic, Head and Neck, and Non–Small Cell Lung Cancer
- (2012) Sarah L. Scarpace CLINICAL THERAPEUTICS
- Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients
- (2012) Kyung Im Kim et al. EUROPEAN JOURNAL OF CANCER
- How aluminum adjuvants could promote and enhance non-target IgE synthesis in a genetically-vulnerable sub-population
- (2012) Todd D. Terhune et al. Journal of Immunotoxicology
- Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
- (2012) David J. Newman et al. JOURNAL OF NATURAL PRODUCTS
- Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
- (2011) M. D. Michaelson et al. ANNALS OF ONCOLOGY
- Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo
- (2011) Sridhar Narayan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells
- (2011) A. V. Singh et al. BLOOD
- Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies
- (2011) P. Schöffski et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer
- (2011) Javier Cortes et al. CANCER TREATMENT REVIEWS
- Water-Soluble Prodrug of Antimicrotubule Agent Plinabulin: Effective Strategy with Click Chemistry
- (2011) Fumika Yakushiji et al. CHEMISTRY-A EUROPEAN JOURNAL
- PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase
- (2011) Yi-He Ling et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
- (2011) Michael Groll et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer
- (2011) Javier Cortes et al. Future Oncology
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies
- (2011) Lia Gore et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis and Structure–Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure
- (2011) Yuri Yamazaki et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
- (2011) Bartomeu Massuti et al. LUNG CANCER
- Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
- (2011) D. G. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Eribulin mesylate
- (2011) Timothy K. Huyck et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-microtubule ‘plinabulin’ chemical probe KPU-244-B3 labeled both α- and β-tubulin
- (2010) Yuri Yamazaki et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
- (2010) G. Germano et al. CANCER RESEARCH
- Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas
- (2010) M. M. Mita et al. CLINICAL CANCER RESEARCH
- Development of cytarabine prodrugs and delivery systems for leukemia treatment
- (2010) Bhupender S Chhikara et al. Expert Opinion on Drug Delivery
- Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era
- (2010) Andrew M. Evens et al. JOURNAL OF CLINICAL ONCOLOGY
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- The Halichondrins and E7389
- (2009) Katrina L. Jackson et al. CHEMICAL REVIEWS
- Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer
- (2009) William B. Parker CHEMICAL REVIEWS
- Multidrug Resistance Through the Spectacle of P-Glycoprotein
- (2009) Katalin Goda et al. CURRENT CANCER DRUG TARGETS
- Antitumor Compounds from Marine Actinomycetes
- (2009) Carlos Olano et al. Marine Drugs
- Kahalalide F, an Antitumor Depsipeptide in Clinical Trials, and Its Analogues as Effective Antileishmanial Agents
- (2009) Luis J. Cruz et al. MOLECULAR PHARMACEUTICS
- Discovery and development of the anticancer agent salinosporamide A (NPI-0052)
- (2008) William Fenical et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells
- (2008) C. M. Sloss et al. CLINICAL CANCER RESEARCH
- Immunological Potential ofHelix vulgarisandRapana venosaHemocyanins
- (2008) Pavlina Dolashka-Angelova et al. IMMUNOLOGICAL INVESTIGATIONS
- Keyhole Limpet Hemocyanin: 9-Å CryoEM Structure and Molecular Model of the KLH1 Didecamer Reveal the Interfaces and Intricate Topology of the 160 Functional Units
- (2008) Christos Gatsogiannis et al. JOURNAL OF MOLECULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started